サポート ブログ Antibody-Drug Conjugates: A New Frontier in Cancer Treatment

Antibody-Drug Conjugates: A New Frontier in Cancer Treatment

Biointron 2024-01-20 Read time: 1 min
ADCs.jpg
Image credit: DOI: 10.1007/s00277-021-04599-5

Antibody-drug conjugates (ADCs) are typically composed of a monoclonal antibody (mAbs) covalently bonded to a biologically active cytotoxic drug via a chemical linker. The mAb can then bind to a specific target protein or receptor, allowing the delivery of the drug into the target cell. 

This combination allows for a highly specific targeting and potent killing effect to achieve accurate and efficient elimination of target cells, without harming healthy cells. This is particularly desirable in treating cancer, as chemotherapy has poor specificity towards tumor tissues and has toxicities to healthy tissues.1

Although most developed ADCs are designed to treat cancer, ongoing research are attempting to use ADCs to treat different diseases such as atherosclerosis, bacteremia, and inflammatory diseases. Furthermore, development of bispecific ADCs, as well as combinations of ADCs with immunotherapy, are anticipated to produce more safe and efficacious therapies.2

At Biointron, we are dedicated to accelerating antibody discovery for the development of antibody-based drugs for various diseases. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.


References:

  1. Pettinato, M. C. (2021). Introduction to Antibody-Drug Conjugates. Antibodies, 10(4). https://doi.org/10.3390/antib10040042 

  2. Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy, 7(1), 1-25. https://doi.org/10.1038/s41392-022-00947-7

Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。